ES2483126T3 - Formulaciones de formas de dosificación de neramexano - Google Patents

Formulaciones de formas de dosificación de neramexano Download PDF

Info

Publication number
ES2483126T3
ES2483126T3 ES11179637.1T ES11179637T ES2483126T3 ES 2483126 T3 ES2483126 T3 ES 2483126T3 ES 11179637 T ES11179637 T ES 11179637T ES 2483126 T3 ES2483126 T3 ES 2483126T3
Authority
ES
Spain
Prior art keywords
weight
dosage form
form according
pharmaceutically acceptable
neramexane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES11179637.1T
Other languages
English (en)
Spanish (es)
Inventor
Erhard Seiller
Bernhard Hauptmeier
Yan Yang
Rajiv Janjikhel
Niranjan Rao
Antonia Periclou
Wattanporn Abramowitz
Mahendra G. Dedhiya
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merz Pharma GmbH and Co KGaA
Original Assignee
Merz Pharma GmbH and Co KGaA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma GmbH and Co KGaA filed Critical Merz Pharma GmbH and Co KGaA
Application granted granted Critical
Publication of ES2483126T3 publication Critical patent/ES2483126T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ES11179637.1T 2004-06-17 2005-06-16 Formulaciones de formas de dosificación de neramexano Expired - Lifetime ES2483126T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58124404P 2004-06-17 2004-06-17
US581244P 2004-06-17

Publications (1)

Publication Number Publication Date
ES2483126T3 true ES2483126T3 (es) 2014-08-05

Family

ID=36953777

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11179637.1T Expired - Lifetime ES2483126T3 (es) 2004-06-17 2005-06-16 Formulaciones de formas de dosificación de neramexano

Country Status (11)

Country Link
EP (3) EP2601937A1 (enExample)
JP (1) JP5025468B2 (enExample)
KR (1) KR20090033410A (enExample)
CN (1) CN101389315A (enExample)
AU (1) AU2005328701B2 (enExample)
BR (1) BRPI0512263A (enExample)
CA (1) CA2568445C (enExample)
EA (1) EA011290B1 (enExample)
ES (1) ES2483126T3 (enExample)
IL (1) IL179992A (enExample)
WO (1) WO2006096194A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2203163B1 (en) * 2007-09-12 2014-08-27 Merz Pharma GmbH & Co. KGaA Titration package for neramexane and its use in the treatment of an inner ear disorder
CA2765609A1 (en) * 2009-06-29 2011-01-06 Merz Pharma Gmbh & Co. Kgaa Method of preparing neramexane
DK2448910T3 (da) * 2009-06-29 2013-06-03 Merz Pharma Gmbh & Co Kgaa Fremgangsmåde til fremstilling af neramexan
PL2448909T3 (pl) * 2009-06-29 2013-09-30 Merz Pharma Gmbh & Co Kgaa Sposób wytwarzania 1-amino-1,3,3,5,5-pentametylocykloheksanu
EP2316434A1 (en) * 2009-10-22 2011-05-04 Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi Orally disintegrating tablets of memantine
US20110294890A1 (en) * 2010-05-28 2011-12-01 Merz Pharma Gmbh & Co. Kgaa Neramexane for the treatment or prevention of inner ear disorders
US8980318B2 (en) * 2010-06-24 2015-03-17 Merz Pharma Gmbh & Co. Kgaa Neramexane multiple unit dosage form
MX2013004123A (es) 2010-10-12 2013-12-16 Univ Johns Hopkins Composiciones antitusigenas que comprenden memantina.
WO2012048871A1 (en) 2010-10-12 2012-04-19 Merz Pharma Gmbh & Co. Kgaa Memantine for improving cognitive performance in subjects
EP2526925A1 (en) 2011-05-23 2012-11-28 Deva Holding Anonim Sirketi A dose adjustable oral pump spray or aerosol spray containing memantine
CN107334744B (zh) * 2017-07-24 2020-09-04 湖南洞庭药业股份有限公司 盐酸美金刚药物组合物和制法
EP4238555A3 (en) * 2019-05-31 2023-09-20 Tecnimede, Sociedade Técnico-Medicinal, SA Immediate release fixed-dose combination of memantine and donepezil
CN114199812A (zh) * 2021-12-28 2022-03-18 南通联亚药业有限公司 一种盐酸美金刚缓释制剂中盐酸美金刚的检测方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7305644A (enExample) 1972-04-20 1973-10-23
DE2856393C2 (de) 1978-12-27 1983-04-28 Merz + Co GmbH & Co, 6000 Frankfurt Arzneimittel zur Behandlung von Morbus Parkinson
US4346112A (en) * 1981-06-29 1982-08-24 University Patents Inc. Composition and method for treating patients having Parkinson's Disease
JPS6216413A (ja) * 1985-07-12 1987-01-24 Teijin Ltd キチン類誘導体を用いた徐放性医薬品組成物
US5506231A (en) 1989-03-31 1996-04-09 The Children's Medical Center Corporation Treatment of aids dementia, myelopathy and blindness
US5334618A (en) 1991-04-04 1994-08-02 The Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
DE58905637D1 (de) 1989-04-14 1993-10-21 Merz & Co Gmbh & Co Verwendung von Adamantan-Derivaten zur Prävention und Behandlung der cerebralen Ischämie.
DE4014672A1 (de) * 1990-05-08 1991-11-14 Werner E G Prof Dr Mueller Verwendung von adamantan-derivaten zur zytoprotektion von nicht-infizierten und virus-infizierten lymphozyten als auch anderen zelltypen
US5614560A (en) 1991-04-04 1997-03-25 Children's Medical Center Corporation Method of preventing NMDA receptor-mediated neuronal damage
US5455279A (en) 1991-04-19 1995-10-03 The Children's Medical Center Corporation Regimen method of mediating neuronal damage using nitroglycerine
EP0581856B1 (en) 1991-04-19 1999-07-14 The Children's Medical Center Corporation Method of preventing nmda receptor complex-mediated neuronal damage
DE4225730C2 (de) 1992-08-04 2003-04-30 Merz Pharma Gmbh & Co Kgaa Verfahren zur Herstellung von festen Arzneiformkörpern mit protrahierter 2-Stufen-Freisetzung
GB9517062D0 (en) * 1995-08-18 1995-10-25 Scherer Ltd R P Pharmaceutical compositions
JPH0971523A (ja) * 1995-09-07 1997-03-18 Riyuukakusan:Kk 口腔内で崩壊性の速い錠剤
AUPN605795A0 (en) 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition
JP3963488B2 (ja) * 1997-06-30 2007-08-22 メルツ ファーマ ゲゼルシャフト ミット ベシュレンクテル ハフツンク ウント コンパニー コマンディゲゼルシャフト アウフ アクチェン １−アミノ−アルキルシクロヘキサンｎｍｄａ受容体拮抗薬
US6071966A (en) 1997-06-30 2000-06-06 Merz + Co. Gmbh & Co. 1-amino-alkylcyclohexane NMDA receptor antagonists
US6413556B1 (en) 1999-01-08 2002-07-02 Sky High, Llc Aqueous anti-apoptotic compositions
SE9901077D0 (sv) 1999-03-23 1999-03-23 Astra Ab Novel use
US6444702B1 (en) 2000-02-22 2002-09-03 Neuromolecular, Inc. Aminoadamantane derivatives as therapeutic agents
TW593223B (en) * 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
US6828462B2 (en) * 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
CA2473536A1 (en) * 2002-01-16 2003-07-31 Endo Pharmaceuticals, Inc. Pharmaceutical composition and method for treating disorders of the central nervous system
TW200306189A (en) 2002-03-21 2003-11-16 Merz Pharma Gmbh & Co Kgaa Azabicyclic, azatricyclic and azaspirocyclic derivatives of aminocyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
FR2841138B1 (fr) * 2002-06-25 2005-02-25 Cll Pharma Composition pharmaceutique solide contenant un principe actif lipophile, son procede de preparation
US20040127541A1 (en) * 2002-07-31 2004-07-01 Janet Codd Bicifadine formulation
AU2004249151A1 (en) * 2003-06-16 2004-12-29 Allergan, Inc. Memantine oral dosage forms
AR046314A1 (es) * 2003-11-05 2005-11-30 Merz Pharma Gmbh & Co Kgaa Composiciones que comprenden ciclohexilaminas y aminoadamantanos
NZ548351A (en) * 2004-01-20 2009-08-28 Novartis Ag Direct compression formulation and process
CA2554959A1 (en) * 2004-01-29 2005-08-11 Neuromolecular, Inc. Combination of a nmda receptor antagonist and a mao-inhibitor or a gadpf-inhibitor for the treatment of central nervous system-related conditions
GT200600008A (es) * 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso

Also Published As

Publication number Publication date
WO2006096194A8 (en) 2007-01-11
CN101389315A (zh) 2009-03-18
AU2005328701B2 (en) 2009-08-13
WO2006096194A2 (en) 2006-09-14
BRPI0512263A (pt) 2008-02-26
IL179992A (en) 2012-02-29
EP2397122B1 (en) 2014-05-14
EP1765287A2 (en) 2007-03-28
WO2006096194A3 (en) 2007-11-22
KR20090033410A (ko) 2009-04-02
EP2601937A1 (en) 2013-06-12
IL179992A0 (en) 2007-05-15
EA200700055A1 (ru) 2007-10-26
JP5025468B2 (ja) 2012-09-12
JP2008509089A (ja) 2008-03-27
EP2397122A3 (en) 2012-01-25
AU2005328701A1 (en) 2006-09-14
EP2397122A2 (en) 2011-12-21
CA2568445C (en) 2011-05-24
CA2568445A1 (en) 2006-09-14
EA011290B1 (ru) 2009-02-27

Similar Documents

Publication Publication Date Title
US8834924B2 (en) Immediate release formulations of 1-aminocyclohexane compounds, memantine and neramexane
JP4340840B2 (ja) 最小化ｐＨ依存性溶解プロフィールを有する徐放性薬学的剤形
ES2370943T3 (es) Composiciones farmacéuticas estabilizadas que comprenden fesoterodina.
KR100728846B1 (ko) 약물 함유량이 높은 정제
US20030158261A1 (en) Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles
ES2483126T3 (es) Formulaciones de formas de dosificación de neramexano
KR20210119906A (ko) 포말리도마이드의 경구용 정제 조성물 및 이의 제조 방법
US20220331305A1 (en) Pharmaceutical Compositions Comprising Alpelisib
US20130323309A1 (en) Sustained Release Composition of Memantine
US20140343076A1 (en) Pharmaceutical compositions of lurasidone
US20110195117A1 (en) Controlled release compositions of ropinirole
HK40084155A (en) Pharmaceutical compositions comprising alpelisib
KR100901927B1 (ko) 메만타인 또는 네라멕산의 직접 압축으로 제조된 마실수 있는 즉시 방출형 제제
US20190151246A1 (en) Delayed-release tablets of methylphenidate
MXPA06014586A (en) Drinkableimmediate release tablet made with direct compression of memantine or neramexane
HK1129584A (en) Immediate release formulations of memantine oral dosage forms
HK1124762A1 (en) Neramexane modified release matrix tablet
HK1220139A1 (zh) 口腔崩解片
HK1124762B (en) Neramexane modified release matrix tablet